About Calliditas Therapeutics

Company Description

Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients.

Recently, we successfully commercialized our lead candidate in the United States, and in collaboration with our partners, launched in Europe, with plans to seek approval in Asia.

Year founded

2004

Headquarters

Kungsbron 1, 11122 Stockholm – Sweden

Shareholder information

Shares outstanding

59,157,587

IPO

Jan. 1, 2000

Stock exchange(s)

Nasdaq Stockholm

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.